Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
PubMed
36758212
DOI
10.1182/blood.2022017976
PII: S0006-4971(23)00365-8
Knihovny.cz E-zdroje
- MeSH
- deficit železa * MeSH
- esenciální trombocytemie * genetika MeSH
- fenotyp MeSH
- hemoglobiny genetika MeSH
- Janus kinasa 2 genetika MeSH
- mutace MeSH
- myeloproliferativní poruchy * farmakoterapie genetika diagnóza MeSH
- myši MeSH
- polycythaemia vera * genetika MeSH
- železo MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- hemoglobiny MeSH
- Janus kinasa 2 MeSH
- železo MeSH
JAK 2-V617F mutation causes myeloproliferative neoplasms (MPNs) that can manifest as polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis. At diagnosis, patients with PV already exhibited iron deficiency, whereas patients with ET had normal iron stores. We examined the influence of iron availability on MPN phenotype in mice expressing JAK2-V617F and in mice expressing JAK2 with an N542-E543del mutation in exon 12 (E12). At baseline, on a control diet, all JAK2-mutant mouse models with a PV-like phenotype displayed iron deficiency, although E12 mice maintained more iron for augmented erythropoiesis than JAK2-V617F mutant mice. In contrast, JAK2-V617F mutant mice with an ET-like phenotype had normal iron stores comparable with that of wild-type (WT) mice. On a low-iron diet, JAK2-mutant mice and WT controls increased platelet production at the expense of erythrocytes. Mice with a PV phenotype responded to parenteral iron injections by decreasing platelet counts and further increasing hemoglobin and hematocrit, whereas no changes were observed in WT controls. Alterations of iron availability primarily affected the premegakaryocyte-erythrocyte progenitors, which constitute the iron-responsive stage of hematopoiesis in JAK2-mutant mice. The orally administered ferroportin inhibitor vamifeport and the minihepcidin PR73 normalized hematocrit and hemoglobin levels in JAK2-V617F and E12 mutant mouse models of PV, suggesting that ferroportin inhibitors and minihepcidins could be used in the treatment for patients with PV.
CSL Vifor St Gallen Switzerland
David Geffen School of Medicine University of California Los Angeles Los Angeles CA
Department of Biology Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic
Division of Genetics and Cell Biology San Raffaele Scientific Institute Milan Italy
Division of Hematology University Hospital Basel Basel Switzerland
Institute of Medical Genetics and Pathology University Hospital Basel Basel Switzerland
Citace poskytuje Crossref.org